Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|1|3|253-257

ISSN： 1574-8863

Source： Current Drug Safety, Vol.1, Iss.3, 2006-08, pp. : 253-257

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologic Therapy in Psoriasis: Safety Profile

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 4-11

Bentham Science Publishers

Access to resources Recommend Favorite

Gene Therapy for Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: Improved Retroviral Vectors for Clinical Trials

By  

Acta Haematologica, Vol. 101, Iss. 2, 1999-04 ,pp. : 89-96

Karger

Access to resources Recommend Favorite

Improving Safety of Gene Therapy

By  

Current Drug Safety, Vol. 3, Iss. 1, 2008-01 ,pp. : 46-53

Bentham Science Publishers

Access to resources Recommend Favorite

Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 22-34

Bentham Science Publishers

Access to resources Recommend Favorite

Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 12-21

Bentham Science Publishers

Access to resources Recommend Favorite